Finanztrends
Deine Einschätzung
Was spricht für und gegen Genetic Technologies Ltd. in den nächsten Jahren?
Pro
?
A****************
?
M************
?
W******* i* V********
Kontra
?
U****************
?
M****
?
L*********** I********** f** d** n******* J****
Sag uns deine Meinung, um die 'Wisdom of the Crowds' zu nutzen
Rendite von Genetic Technologies Ltd. im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Genetic Technologies Ltd. | - | - | - | - | - | - | - |
| Invion Ltd | 0,00 % | 0,00 % | 0,00 % | -40,00 % | -47,50 % | 4100,00 % | 320,00 % |
| Immutep LTD ADR | 4,79 % | 4,79 % | -5,41 % | -76,03 % | -86,54 % | -81,77 % | -88,85 % |
| Arovella Therapeutics Ltd. | -1,39 % | 0,00 % | -6,58 % | -24,47 % | -14,46 % | 65,12 % | 47,92 % |
Kommentare
News
Black Diamond Therapeutics Touts Silevertinib Lung Cancer Data, Eyes FDA Path
Key Points
- Interested in Black Diamond Therapeutics, Inc.? Here are five stocks we like better.
- Silevertinib showed encouraging Phase 2 lung cancer data, including a 60% objective response
Pelthos Therapeutics Q1 Earnings Call Highlights
Pelthos Therapeutics (NYSEAMERICAN:PTHS) reported higher first-quarter revenue as prescriptions for its lead product, ZELSUVMI, continued to grow in the treatment’s third full quarter since launch